THEMISMED132.00

Themis Medicare Limited

· Pharma & Health
₹ CrorePeersLINCOLNBAJAJHCARESIGACHIWANBURYAMRUTANJANAHCLANUHPHRMcap ₹1,216 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Returns
Return on Common Equity11.527.410.290.29
Return on Assets7.685.070.190.19
Return on Capital Employed9.539.06-2.30-2.30
Return on Invested Capital6.045.79-2.01-6.49
Margins
EBITDA Margin13.4912.100.11-12.65
Operating Margin10.289.65-2.90-2.90
Incremental Operating Margin-0.5977.51
Pretax Margin9.078.32-3.5411.40
Net Income Margin11.407.360.3312.05
Net Income to Common Margin11.407.360.3312.05
FCF Margin-1.044.76-2.38-2.38
Additional
Effective Tax Rate28.6429.16-6.4738.65
Dvd Payout Ratio10.5715.43402.38
Sustainable Growth Rate10.306.27-0.880.29
Incremental Operating Margin %-0.5977.51398.54
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.